Current Report Filing (8-k)
25 1월 2023 - 6:06AM
Edgar (US Regulatory)
0001158780
false
0001158780
2023-01-23
2023-01-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January
24, 2023 (January 23, 2023)
PLURI INC.
(Exact Name of Registrant as Specified in Its Charter)
Nevada |
|
001-31392 |
|
98-0351734 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
MATAM Advanced Technology Park |
|
|
Building No. 5 |
|
|
Haifa, Israel |
|
3508409 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
011 972 74 710 7171
(Registrant’s telephone number, including area
code)
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Shares, par value $0.00001 per share |
|
PLUR |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an
emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
As previously disclosed, on
October 12, 2022, Pluri Inc. (the “Company”) received a letter (the “Notice”)
from the listing qualifications staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying
the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued
listing. On January 23, 2023, the Company received a letter from the Staff notifying
the Company that the Staff has determined that for the last 10 consecutive business days, from January 6, 2023 to January 23, 2023, the
closing bid price of the Company’s common stock had been at $1.00 per share or greater and that accordingly, the Company has regained
compliance with Nasdaq Listing Rule 5550(a)(2) and the matter is now closed.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PLURI INC. |
|
|
Date: January 24, 2023 |
By: |
/s/ Chen Franco-Yehuda |
|
Name: |
Chen Franco-Yehuda |
|
Title: |
Chief Financial Officer |
Pluristem Therapeutics (NASDAQ:PSTI)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Pluristem Therapeutics (NASDAQ:PSTI)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
Pluristem Therapeutics Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Pluri Inc. News Articles